Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 24, Issue 5, Pages 823-834Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2005.03.8471
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA103985] Funding Source: Medline
- NIBIB NIH HHS [EB002114] Funding Source: Medline
Ask authors/readers for more resources
This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor: background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available